Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Regeneron Pharmaceuticals Inc. (NASDAQ ... in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

PORTLAND, OR, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The global atopic dermatitis market is witnessing unprecedented growth, projected to expand from $5.3 billion in 2021 to $22.6 billion ...

Among a study population of adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis (AD) and skin of color, dupilumab (Dupixent; Regeneron Pharmaceuticals and Sanofi) ...